Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 10

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Hepatol. Oct 27, 2025; 17(10): 110402
Published online Oct 27, 2025. doi: 10.4254/wjh.v17.i10.110402

Full Size Figure Download Figure

Figure 6 Kyoto Encyclopedia of Genes and Genomes enrichment analysis pointed out the top 20 hepatic pathways by bubble mapping.

Citation: Niu S, Chen SC, Wang CX, Yue L, Wang SQ. Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice. World J Hepatol 2025; 17(10): 110402
URL: https://www.wjgnet.com/1948-5182/full/v17/i10/110402.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i10.110402

Niu S, Chen SC, Wang CX, Yue L, Wang SQ. Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice. World J Hepatol 2025; 17(10): 110402 [PMID: 41179732 DOI: 10.4254/wjh.v17.i10.110402]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.